| Quarter (USD) | Sep 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 60.92 mm | 60.92 mm | 60.92 mm | 60.92 mm | 60.92 mm | 60.92 mm |
| Cash burn (monthly) | 7.48 mm | 7.83 mm | 8.88 mm | 9.92 mm | 7.57 mm | 8.98 mm |
| Cash used (since last report) | 20.94 mm | 21.93 mm | 24.84 mm | 27.78 mm | 21.20 mm | 25.13 mm |
| Cash remaining | 39.97 mm | 38.99 mm | 36.07 mm | 33.14 mm | 39.72 mm | 35.79 mm |
| Runway (months of cash) | 5.3 | 5.0 | 4.1 | 3.3 | 5.2 | 4.0 |
| 13F holders | Current |
|---|---|
| Total holders | 24 |
| Opened positions | 10 |
| Closed positions | 26 |
| Increased positions | 5 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 2.08 bn |
| Total shares | 7.83 mm |
| Total puts | 28.10 k |
| Total calls | 54.20 k |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Katz Daryl | 6.05 mm | $4.60 mm |
| Rosalind Advisors | 607.80 k | $1.04 bn |
| Shikiar Asset Management | 225.97 k | $387.00 k |
| Gsa Capital Partners | 195.28 k | $334.00 k |
| Nantahala Capital Management | 153.15 k | $261.89 mm |
| National Asset Management | 120.81 k | $206.59 mm |
| Cambridge Investment Research Advisors | 88.90 k | $152.00 k |
| Millennium Management | 65.18 k | $111.45 mm |
| 180 Wealth Advisors | 62.35 k | $122.83 mm |
| Commonwealth Equity Services | 61.70 k | $106.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 19 Dec 24 | David Jin | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 0 | 1,000,000 | 0.00 | 1,240,893 |
| 1 Oct 24 | David Jin | Common Stock, par value $0.001 | Grant | Acquire A | No | No | 1.2283 | 2,625 | 3.22 k | 240,893 |
| 27 Sep 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 146,341 | 0.00 | 3,735,534 |
| 23 Sep 24 | Rosenwald Lindsay A MD | Common stock, par value $0.001 | Buy | Acquire P | No | No | 1.84 | 763,359 | 1.40 mm | 3,657,264 |
| 23 Sep 24 | Rosenwald Lindsay A MD | Warrants to Purchase Common Stock Common Stock | Buy | Acquire P | No | No | 0.125 | 763,359 | 95.42 k | 763,359 |
| 11 Jul 24 | Rosenwald Lindsay A MD | SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | Buy | Acquire P | No | No | 7.4835 | 5,000 | 37.42 k | 127,500 |
